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Background: The purpose of this study was to evaluate corneal parameters in treated glaucoma 
patients, nontreated glaucoma patients, and normal subjects using confocal microscopy.
Methods: Forty patients with primary open-angle glaucoma and 22 untreated controls under-
went confocal microscopy of the cornea using the Heidelberg retinal tomograph cornea module. 
The glaucoma group was divided into two subgroups, ie, patients on medical treatment for at 
least two years before inclusion (with beta-blockers or prostaglandin analogs) and nontreated 
glaucoma patients. The following corneal parameters were evaluated: endothelial cell density 
and number, reflectivity, and tortuosity of sub-basal nerves. For reflectivity and tortuosity, a 
dedicated grading scale ranging from 0 to 4 was used. Differences between treatments were 
also evaluated in the treated glaucoma group.
Results: Number of fibers and reflectivity of the sub-basal plexus were significantly lower in 
glaucoma patients as compared with controls (2.5 ± 0.7 versus 2.9 ± 0.9, P = 0.006, and 2.3 ± 0.8 
versus 2.7 ± 0.9, P = 0.04, respectively), whereas tortuosity was significantly higher (2.6 ± 1 
versus 2.0 ± 0.8, P = 0.007). Endothelial cell density (measured as cells per mm2) was lower 
in the glaucoma group comparing treated patients with nontreated patients (2826 ± 285 versus 
3124 ± 272, P = 0.0003). Comparing treated patients with nontreated patients, relevant differ-
ences were found in number (2.3 ± 0.7 versus 2.8 ± 0.8, P = 0.004), tortuosity (2.8 ± 1 versus 
2.2 ± 0.8, P = 0.004), and reflectivity (2.2 ± 0.8 versus 2.6 ± 0.8, P = 0.04). No differences in 
corneal parameters were found between beta-blockers and prostaglandin analogs.
Conclusion: This study shows that differences in corneal parameters between glaucoma 
patients and controls may be due to the medical treatments used for glaucoma. These data 
should be taken into consideration in long-standing medical glaucoma treatment and in potential 
candidates for surgery.
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Introduction
Glaucoma is an optic neuropathy characterized by structural changes and functional 
 impairment. It can be divided into primary open-angle glaucoma, which has an insidious 
and slow onset, and angle-closure glaucoma. Quigley and Broman1 estimate that glaucoma 
affects 60.5 million people worldwide and that this number will increase to about 80 million 
by 2020. Approximately 75% of these patients will have primary open-angle glaucoma. 
Glaucoma is the second leading cause of blindness in the world and would account for 
over eight million cases of blindness today, rising to over 11 million by 2020.1
Treatments for glaucoma aim at reducing intraocular pressure, which is the main 
risk factor for development and progression of the disease. Medical, surgical, and 
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laser options are available. Topical medical treatments are 
effective in most cases. Even if monodose treatments are 
available for beta-blockers and, very recently, for prostaglan-
din analogs, multidose treatments are more frequently used. 
Multidose formulations require the use of a  preservative in 
order to guarantee the absence of contamination by micro-
organisms. Unfortunately, this toxic effect is aspecific and 
generates dose-dependent noxious effects on the ocular 
surface.
Glaucomatous patients often need to use more than one 
eye drop to obtain adequate reduction in intraocular pressure, 
and topical therapy is carried on for many years or lifelong, 
so adverse events and side effects should be minimized 
to achieve optimal compliance. Therefore, ocular surface 
impairment in glaucoma has become a topic of great interest. 
The negative effects of glaucoma medications may be due 
to both allergic and toxic mechanisms in the conjunctiva, 
lacrimal film, and cornea.2 These effects may be due to the 
active component, as well as to preservatives, but the exact 
mechanisms involved in inducing toxic or proinflammatory 
effects of ophthalmic solutions are still unknown.3 Among 
the side effects, ocular surface disorders attributable to the 
drug itself or to drug preservatives are relatively common.4–9 
Furthermore, the use of antiglaucoma drugs may induce 
cytotoxicity in corneal endothelial cells, as shown by in 
vitro studies.10,11
Confocal microscopy is a novel diagnostic technique 
which provides noninvasive optical sectioning of the 
 tissues of the anterior segment of the eye and allows 
high-magnification imaging of the corneal epithelium, 
Bowman’s membrane, stromal keratocytes, and nerves, 
as well as the corneal endothelium. Confocal imaging is 
able to show changes on the ocular surface in a number of 
subclinical eye conditions.12–15 The aim of this study was 
to investigate with confocal microscopy in vivo the sub-
basal corneal plexus and endothelial cell involvement in 
medical treatment of glaucoma.
Materials and methods
Patients
This study was conducted at the Eye Clinic of the University 
of Milan, San Paolo Hospital, Milan, Italy, was approved by 
the local ethics committee, and adhered to the tenets of the 
Declaration of Helsinki. Informed consent was obtained from 
all patient before enrolment.
Caucasian patients with primary open-angle glaucoma 
referred to the glaucoma service from April 2009 to October 
2009 were considered for the study. Inclusion criteria were 
a diagnosis of glaucoma defined by glaucomatous optic disc 
changes and corresponding visual field defects, based on 
the European Glaucoma Society Guidelines criteria.16 Only 
patients with intraocular pressure not over 24 mmHg on 
repeated measurements were enrolled. Glaucoma patients 
were divided into two subgroups, ie, patients who had had 
medical treatment (with beta-blockers or prostaglandin 
 analogs) for at least two years before inclusion and nontreated 
glaucoma patients. Exclusion criteria were ocular trauma, 
corneal changes of any kind, media opacities, history of ocu-
lar surgery other than for uncomplicated cataract, current use 
of contact lens, and autoimmune disease. Forty consecutive 
patients who fulfilled the inclusion and exclusion criteria and 
22 normal subjects were enrolled in the study.
study procedures
A medical history was taken for all the participants. All the 
subjects underwent a complete ophthalmic examination, 
including anterior segment biomicroscopy and fundus 
 examination, refraction, and measurement of best corrected 
visual acuity using the Early Treatment of Diabetic Retin-
opathy Study chart. In vivo laser scanning confocal micros-
copy of the cornea was performed using the Heidelberg 
Retina Tomograph 2-Rostock cornea module (Heidelberg 
Engineering, Dossenheim, Germany). Data were collected 
for both eyes, and one eye for each patient was chosen at 
random (unless only one eye met the inclusion criteria) for 
analytical purposes.
in vivo laser confocal microscopy  
of cornea
The Heidelberg retina tomograph (HRT) was initially 
designed to evaluate the optic nerve head in glaucoma. The 
second HRT version, endowed with a lens system, known 
as the Rostock cornea module (RCM), allows in vivo con-
focal study of the cornea layers.17 The laser source used 
in the RCM is a diode laser with a wavelength of 670 nm. 
The two-dimensional images acquired have a definition of 
384 × 384 pixels over an area of 400 µm × 400 µm, with 
lateral digital resolution of 1 µm/pixel and a depth resolution 
of 2 µm/pixel.
Data collection
After administration of one drop of 0.4% oxybuprocaine 
(Novesine®; MSD-Chibret, Paris, France) and one drop 
of a lubricant gel, 0.2% carbomer (Lacrigel®; Europhtha, 
Monaco) the patient was asked to fixate on a small bright 
red light while the examination was performed in the 
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 contralateral eye.  Correct alignment and contact with the 
cornea were monitored using the images captured by a 
camera tangential to the eye. The distance from the cornea 
to the microscope was kept stable using a single-use con-
tact element in sterile packaging (TomoCap®; Heidelberg), 
which is a thin cap with a planar contact surface made from 
polymethyl methacrylate and is coupled optically to the lens 
with the aid of a gel.
A scan of the full thickness of the cornea was performed 
along the optical axis, and no tangential movements were 
allowed in order to prevent biased acquisitions. The examina-
tion took about three minutes per eye and about 120 images 
were collected. Only images of the center of the cornea were 
collected. The best-focused sub-basal plexus and endothelial 
cell images were considered for the analysis.
The following parameters of the sub-basal plexus nerves 
were considered: number per frame, and tortuosity and 
reflectivity of fibers. The last two parameters were evaluated 
by comparison with the reference images according to the 
method proposed by Oliveira-Soto and Efron, and graded 
from 0 to 4.18 The HRT Rostock cornea module also has a 
semi-automated system for endothelial cell counting. On 
the best focused endothelial cell image, a region of interest 
is selected, cells are marked, and the system automatically 
calculates cell density.
Agreement
All study examinations were performed by a single masked 
expert operator (SR). Before the study began, the reproduc-
ibility of data was tested using the following procedure. The 
evaluator collected five scans of the plexus of a volunteer 
along the corneal axis, and during the same day, at intervals 
of 60 minutes and at the end of each acquisition, selected the 
best-focused image of the plexus. Masking was obtained by 
an independent investigator mixing these five images with 
10 control images, and the operator was asked to grade all 
images considering number, tortuosity, and reflectivity of 
fibers. For each parameter, agreement of the five images 
was defined in the presence of values within ±1 of the mean 
value, this cutoff value being derived from previous studies 
on corneal confocal microscopy.18 Intraobserver agreement 
for image scores were calculated using the intraclass correla-
tion coefficient as follows:
Intraclass correlation coefficient = σa2/(σ2 + σa2)
where σ2 = QM(e), or intraclass variability: σa2 = [QM(a)-
QM(e)]/n or (interclass - intraclass variability)/number of 
classes.19 Agreement was defined according to the guide-
lines proposed by Landis and Koch:20 chance agreement, 
0.01–0.19; poor agreement, 0.20–0.39; fair agreement, 
0.40–0.59; moderate agreement, 0.60–0.79; and substantial 
agreement, 0.80–1.00. For our series of data, agreement was 
0.70 for tortuosity, 0.75 for reflectivity, and 0.9 for number 
of fibers.
statistical analysis
Intergroup differences were evaluated using the t-test for 
unpaired data. Differences with P , 0.05 were deemed 
to be statistically signif icant. All statistical analyses 
were calculated using the SPSS (version 15.0, SPSS Inc, 
 Chicago, IL).
Results
The demographic characteristics of the patients are 
 summarized in Table 1. Mean age and gender were not 
significantly different between the glaucoma patients and 
controls (P = 0.18, t-test, and P = 0.80, X 2, respectively).
The numbers of nerve fibers (2.5 ± 0.7 versus 2.9 ± 0.9, 
P = 0.006) and reflectivity of fibers (2.3 ± 0.8 versus 2.7 ± 0.9, 
P = 0.04) of the sub-basal plexus were significantly lower in 
glaucoma patients as compared with controls, whereas tortuos-
ity was significantly higher (2.6 ± 1 versus 2.0 ± 0.8, P = 0.007, 
Figure 1). Endothelial cell density (given as cells/mm2) was 
lower in the glaucoma group (2925 ± 313 versus 3187 ± 312, 
P = 0.0003).
Table 1 Demographics of study participants
A normal  
subjects
B glaucoma  
patients
B1 beta-blockers B2 prostaglandin  
analogs
B3 nontreated  
glaucoma patients
subjects (n) 22 40 12 12 16
Age, years (sD) 62.5 ± 8 62.5 ± 6 61.5 ± 6 63.5 ± 6 62.6 ± 5
gender 10 F, 12 M 20 F, 20 M 7 F, 5 M 6 F, 6 M 7 F, 9 M
iOP, mmhg (sD) 17.1 ± 2.0 18.3 ± 2.4 18.2 ± 1.9 18.4 ± 2.8 22.3 ± 2.6
Refraction, diopters (sD) -1.35 ± 1.49 -1.30 ± 1.20 -1.28 ± 2.10 -1.30 ± 1.75 -1.31 ± 1.23
CCT (µm) 553 ± 20 548 ± 23 548 ± 27 550 ± 24 546 ± 25
Abbreviations: sD, standard deviation; iOP, intraocular pressure; CCT, central corneal thickness; F, female; M, male.
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Comparing treated and untreated glaucoma patients, 
significant differences were found in nerve fiber number 
(2.3 ± 0.7 versus 2.8 ± 0.8, P = 0.004), tortuosity (2.8 ± 1 
versus 2.2 ± 0.8, P = 0.004), reflectivity (2.2 ± 0.8 versus 
2.6 ± 0.8, P = 0.04), and endothelial cell density (2826 ± 285 
versus 3124 ± 272, P = 0.0004). No differences were found 
between prostaglandin analogs and beta-blockers for nerve 
number (P = 0.8), tortuosity (P = 1), reflectivity (P = 0.9), or 
number of endothelial cells (P = 0.9). Normal subjects and 
untreated glaucoma patients had similar numbers (P = 0.5), 
tortuosity (P = 0.5), and reflectivity (P = 0.6) of nerve fibers 
and endothelial cell counts (P = 0.4).
Discussion
Several studies have demonstrated that long-term use of 
intraocular pressure-lowering treatments frequently cause 
chronic changes on the ocular surface6,15 due to the drug itself 
or to preservatives.6,20 Benzalkonium chloride is the most 
commonly used preservative in ophthalmic  preparations. It is 
a quaternary ammonium compound with potent antimicrobial 
effects, but also with relevant dose-dependent side effects on 
the cornea and conjunctiva.21,22 Due to these characteristics, 
it has been suggested that benzalkonium chloride be con-
sidered as an active compound, the concentration of which 
should be specified for the product (a fact that, to date, is 
A B
C D
Figure 1 subbasal nerves plexus of normal subject (A), nontreated glaucoma patient (B), prostaglandin analog treated patient (C) and beta-blocker treated patient (D).
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not compulsory in many countries, including Italy). Current 
intraocular pressure-lowering treatments have benzalkonium 
chloride concentrations ranging from 0.01% to 0.005%, even 
if the recommended concentration is less than 0.005%.22 
Other less toxic preservatives have been studied and are now 
clinically available in the glaucoma field, ie, SofZia® (Alcon 
Inc. Hünenberg, Switzerland), Purite® (Allergan, Inc. Irvine, 
CA),23 and  Poliquad® (Alcon Inc. Hünenberg, Switzerland). 
It has been suggested that inflammatory mechanisms com-
bining allergy with toxicity are involved in the complexity 
of reactions occurring at the ocular surface in patients using 
preserved topical glaucoma treatments.2
The recent introduction of confocal microscopy allows clini-
cal insights at cellular levels, which was impossible with tradi-
tional in vivo diagnostics used in clinical practice. In this study, 
we performed a confocal examination of the cornea in glaucoma 
patients receiving intraocular pressure-lowering treatments for at 
least two years, compared with untreated glaucoma patients and 
controls, and showed that treated patients had relevant changes 
in systolic blood  pressure and endothelial cell density.
Nerve fibers are important for corneal trophism and for 
maintaining a healthy ocular surface.24 A lower nerve den-
sity may impair corneal sensitivity, as observed in glaucoma 
patients.25 Overall, our data confirm the findings by Martone 
et al26 who showed a decrease in number of nerve fibers and an 
increase in tortuosity at confocal microscopy in treated glaucoma 
patients compared with controls. Compared with that study, we 
found differences in corneal parameters in the control group 
(2.9 ± 0.9 versus 5.26 ± 1.3 and 2.0 ± 0.8 versus 1.2 ± 0.39) for 
number of nerves and tortuosity, respectively, as in the glaucoma 
group. These findings may be due to differences in the study 
populations (most likely due to the higher duration of therapy in 
our study), and also to the poor interobserver reproducibility of 
confocal microscopy. Also, a lower fiber reflectivity was found 
in our glaucoma group, which may be due to the absence of 
correction for reflectivity of Bowman’s membrane.
The second confocal parameter evaluated in this study 
was endothelial cell density. It has been shown that corneal 
endothelial cell survival, after chronic exposure to com-
mercially available eye drops, is longer in the absence 
of a preservative.27 Even if there is some evidence that 
intraocular pressure-lowering treatments may damage or 
interfere with the normal physiologic functions of the corneal 
endothelium,28 the endothelial cell count was not considered 
in previous confocal studies. Our study is the first to show that 
a lower endothelium density is present in patients receiving 
antiglaucoma drugs by means of confocal microscopy.
A strength of this study was the inclusion of a group of 
untreated glaucoma patients, which allowed us to show that 
our untreated glaucoma patients and controls had similar 
corneal parameters, thus demonstrating that the corneal 
damage observed was not due to glaucoma itself but to the 
therapy used.
All confocal studies should be evaluated with caution 
given the limitations of this technique, ie, it is a qualitative 
and subjective examination, the reproducibility of which has 
not been fully explored. Also, we limited our investigations 
to the center of the cornea, and different results might be 
obtained by inspecting the corneal periphery.
In conclusion, this study confirms that, in addition to 
intraocular pressure-lowering effects, specific preserved 
topical glaucoma treatments induce changes at the ocular 
surface which can be well documented by means of  confocal 
microscopy. In the balance between efficacy and toler-
ability, it must be kept in mind that formulations with low 
 cytotoxicity (ie, low or absent concentrations of preservative, 
or containing preservatives less toxic than benzalkonium 
chloride) may guarantee fewer side effects, with higher 
tolerability and better compliance.
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